Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Submits BRACAnalysis CDx for Approval in Japan

NEW YORK (GenomeWeb) – Myriad Genetics has submitted BRACAnalysis CDx for review by Japan's Pharmaceutical Medical Devices Agency and for marketing approval by its Ministry of Health, Labor and Welfare.

If approved, the companion diagnostic can be used to identify which HER2-negative, metastatic breast cancer patients have germline mutations in BRCA1 and BRCA2 genes and are likely to respond to AstraZeneca's Lynparza (olaparib).

"This regulatory submission as a companion diagnostic for a PARP inhibitor outside the US reflects another important major milestone as Myriad seeks to become a global leader in personalized medicine,” Myriad CEO Mark Capone said in a statement.

Myriad will perform testing for the Japanese market in its US lab. The company estimated that in Japan each year there are more than 10,000 cases of HER2-negative metastatic breast cancer eligible for testing with BRACAnalysis CDx.

Earlier this month, the company said that the US Food and Drug Administration had accepted its supplementary premarket approval application for BRACAnalysis CDx alongside Lynparza in the same breast cancer setting. The test is already approved as a CDx for Lynparza for patients with germline BRCA-mutated advanced ovarian cancer, who have received three or more prior lines of chemotherapy.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.